Darzalex and Revlimid upkeep improves survival following autologous stem cell transplantation in a number of myeloma: © inventory.adobe.com.
Upkeep remedy with Darzalex (daratumumab) and Revlimid (lenalidomide) resulted in superior outcomes in contrast with standard-of-care Revlimid alone following autologous stem cell transplantation in sufferers with newly recognized a number of myeloma, in line with information from the part 3 AURIGA examine.
The AURIGA examine evaluated remedy responses amongst 200 sufferers with newly recognized a number of myeloma who skilled superb or higher partial responses, had been MRD-positive and anti-CD38-naïve following transplant. By 12 months from the beginning of upkeep remedy, 50.5% of the 99 sufferers within the Revlimid and Darzalex arm had achieved minimal residual illness (MRD) negativity, versus 18.8% of the 101 sufferers within the standalone Revlimid arm, researchers reported.
At a median follow-up of 32.3 months, 60.6% of sufferers within the mixture arm had achieved MRD negativity versus 27.7% of sufferers who acquired Revlimid alone, whereas full response charges or higher had been 75.8% and 61.4%, respectively. The speed of sustained MRD negativity lasting no less than six months within the mixture arm was roughly 2.5 occasions that of sufferers within the Revlimid arm, at 35.4% versus 13.9%.
Glossary
Autologous stem cell transplantation: when a affected person’s wholesome blood-forming cells are collected and saved earlier than remedy then given again to the affected person after remedy.
Minimal residual illness: a small variety of most cancers cells that stay within the physique after remedy.
Development-free survival: the time {that a} affected person lives with out their illness spreading or worsening.
Cytopenias: low ranges of pink blood cells, white blood cells or platelets.
Myelodysplastic syndrome: cancers the place immature blood cells within the bone marrow don’t mature or turn out to be wholesome blood cells.
Peripheral sensory neuropathy: harm to the nerves outdoors of the mind and spinal wire.
Researchers additional famous that 30-month progression-free survival charges had been 82.7% for sufferers within the mixture arm and 66.4% for sufferers who solely acquired Revlimid upkeep remedy.
“These outcomes help the addition of [Darzalex] not solely to induction/consolidation, but in addition to [standard-of-care Revlimid] upkeep for these sufferers,” mentioned Dr. Ashraf Z. Badros and fellow researchers of their findings revealed in Blood. “Future research ought to proceed to evaluate the implementation of [Darzalex]-based upkeep in different affected person populations and decide the optimum level of remedy initiation and cessation.”
Badros is a professor of medication with the College of Maryland Medical System in Baltimore.
Darzalex, in line with the Nationwide Most cancers Institute, binds to the protein CD38 discovered on some varieties of immune cells and most cancers cells, together with myeloma cells, and should block CD38 and assist the immune system kill most cancers cells. Revlimid could assist the immune system kill irregular blood cells or most cancers cells, in line with the Nationwide Most cancers Institute.
Security Information and Extra Data on the AURIGA Examine
Concerning security, sufferers within the mixture arm skilled larger charges of grade 3 (extreme) and 4 (life-threatening) cytopenia’s (54.2% versus 46.9%) and infections (18.8% versus 13.3%) than sufferers who acquired Revlimid upkeep monotherapy.
Among the many 194 sufferers who acquired no less than one dose of examine remedy — 96 sufferers within the mixture arm, 98 within the Revlimid alone arm — treatment-related uncomfortable side effects of any grade had been reported in 99% of sufferers in each teams, with grade 3 or 4 uncomfortable side effects occurring in 74% and 67.3% of sufferers, respectively. Critical uncomfortable side effects had been reported amongst 30.2% and 22.4% of sufferers, with essentially the most frequent being pneumonia at 4.2% and 4.1%, respectively.
Uncomfortable side effects resulted in remedy discontinuation for 14.6% and eight.2% of sufferers, mostly on account of myelodysplastic syndrome for the mix arm (2.1%) and peripheral sensory neuropathy for the Revlimid arm (2%). Deadly uncomfortable side effects had been reported in two sufferers within the mixture arm (one every on account of COVID-19 pneumonia and Legionella pneumonia) and one affected person within the Revlimid monotherapy arm, on account of COVID-19 pneumonia.
“Within the randomized, part 3 AURIGA examine, the addition of [Darzalex] to [Revlimid] upkeep resulted in a considerably larger MRD-negative conversion fee amongst transplant-eligible sufferers with [newly diagnosed multiple myeloma] who had [a very good partial response or better], had been MRD-positive and had been anti-CD38–naïve after [autologous stem cell transplantation], in contrast with [Revlimid] upkeep alone,” Badros and colleagues wrote. “This enhance in MRD-negative conversion was clinically significant on condition that [Darzalex-Revlimid] upkeep trended towards improved [progression-free survival], larger total MRD-negative conversion charges and deeper responses in contrast with [Revlimid] upkeep alone, with no sudden security issues.”
Reference
“Daratumumab with lenalidomide as upkeep after transplant in newly recognized a number of myeloma: the AURIGA examine” by Ashraf Badros, et al., Blood.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
